Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Delayed-release Tablets in the United States
The agreement also includes rights to posaconazole 40mg/mL oral suspension which Par intends to launch in the coming months.
- The agreement also includes rights to posaconazole 40mg/mL oral suspension which Par intends to launch in the coming months.
- "Paris pleased to provide patients and providers with access to a lower-cost treatment through our launch of the authorized generic version of Noxafil," said Domenic Ciarico, Executive Vice President & Chief Commercial Officer, Sterile & Generics at Endo.
- Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA.
- Because these statements reflect Endo's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties.